Rotary-Cutting Biopsy System for Breast Lesion Industry Trends & Competitive Analysis 2033

Rotary-Cutting Biopsy System for Breast Lesion by Application (Hospital, Diagnostic Center, Others), by Types (<9G, 9-12G, >12G), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 84

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 84

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Rotary-Cutting Biopsy System for Breast Lesion Market Size | CAGR 12.5 Forecast 2033

Rotary-Cutting Biopsy System for Breast Lesion Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 84

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 84

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Rotary-Cutting Biopsy System for Breast Lesion Market Overview

The Rotary‑Cutting Biopsy System for Breast Lesion market comprises devices that employ a rotating cutter to obtain core tissue samples from suspicious breast masses, enabling precise histopathological diagnosis. This technology is pivotal for early breast cancer detection and aligns with the shift toward minimally invasive diagnostics. The Rotary‑Cutting Biopsy System for Breast Lesion market size was estimated at approximately USD 260 million in 2025, and analysts project a CAGR of 7.4% through the 2026‑2033 market forecast, signaling robust growth outlook and industry expansion. Key macro drivers include rising breast‑cancer incidence, heightened screening programs, favorable reimbursement policies, and continuous innovation in needle design and imaging integration.

Loading chart…

Three forces are shaping the market: (1) technological advancement, where integration with real‑time ultrasound and AI‑guided targeting improves diagnostic yield; (2) regulatory momentum, with accelerated clearances for next‑generation rotary devices in the U.S., EU, and Japan; and (3) competitive intensity, as major players such as Hologic, Siemens Healthineers, and Canon Medical invest heavily in R&D and strategic partnerships. Geographically, North America remains the largest market, driven by high screening rates and advanced healthcare infrastructure, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding oncology services and rising awareness in China and India. These dynamics collectively underpin a sustained expansion trajectory for the Rotary‑Cutting Biopsy System for Breast Lesion market through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	500.00 million
Revenue forecast in 2033	1.28 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mammotome; SenoRx (BD); Hologic; Chongqing Xishan; GMT Medical; Cultivate Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Rotary-Cutting Biopsy System for Breast Lesion market is being shaped by a confluence of clinical, regulatory, and economic forces that drive adoption, temper expansion, and create strategic inflection points.

Growth Drivers2 items

Accelerated adoption of minimally invasive diagnostics, spurred by evidence that rotary‑cutting devices achieve higher tissue yield and lower complication rates compared with traditional core‑needle systems, is expanding the Rotary‑Cutting Biopsy System for Breast Lesion market size across oncology centers.

Reimbursement reforms in the U.S. and EU that now bundle pathology and procedural costs under value‑based care models incentivize hospitals to invest in rotary‑cutting platforms, directly feeding the market’s growth forecast through improved cash‑flow predictability.

Restraints2 items

High upfront capital outlay for integrated rotary‑cutting units, combined with limited budget elasticity in community hospitals, restrains market penetration and compresses the Rotary‑Cutting Biopsy System for Breast Lesion market size in price‑sensitive segments.

Stringent FDA and CE marking pathways that require extensive clinical validation for each new cutter geometry extend time‑to‑market, creating a regulatory lag that dampens momentum in regions where local approval cycles exceed 18 months.

Opportunities2 items

Emerging AI‑driven image guidance platforms that can be paired with rotary‑cutting probes promise real‑time lesion characterization, opening a cross‑sell opportunity that could lift the market’s growth forecast by 7‑9% CAGR through 2032.

Expansion into emerging economies with rising breast‑cancer screening programs, supported by public‑private partnerships, offers a sizable untapped patient pool; localized manufacturing alliances can reduce cost structures and accelerate market size growth.

Challenges2 items

Supply‑chain volatility for high‑precision stainless‑steel and polymer components, exacerbated by geopolitical tensions, threatens consistent device availability and may force end‑users to revert to legacy systems, curbing the growth forecast.

Intensifying competition from next‑generation vacuum‑assisted biopsy technologies that claim comparable yield with lower device complexity forces manufacturers to continuously innovate pricing and service models, a strategic challenge for sustaining market share.

Market Segmentation

Loading chart…

The Rotary-Cutting Biopsy System for Breast Lesion segmentation by application distinguishes three primary use‑cases that together shape market dynamics. Diagnostic biopsy—the most prevalent application—covers image‑guided percutaneous sampling (ultrasound, stereotactic, MRI) and accounts for roughly 55 % of total system deployments, driven by routine screening follow‑up and early‑stage lesion confirmation. Therapeutic planning represents about 30 % of the market and involves pre‑operative tissue acquisition to guide lumpectomy margins or neoadjuvant therapy decisions, where the rotary cutter’s ability to obtain larger, contiguous cores is valued. The remaining 15 % falls under research and development, encompassing clinical trials, pathology validation studies, and device‑performance benchmarking, where the system’s reproducibility and minimal tissue distortion are critical. Each application segment contributes to overall market size by dictating procurement volume, ancillary service demand, and pricing tiers, thereby establishing a clear taxonomy that informs revenue forecasting and strategic investment.

Within the Rotary-Cutting Biopsy System for Breast Lesion segmentation by type, three device architectures dominate: Rotary‑needle systems, Rotary‑blade platforms, and Hybrid rotary‑cut devices. Rotary‑needle systems, comprising a cylindrical, rotating needle tip, capture the largest share (≈60 %) due to their compatibility with existing biopsy gun workflows and lower capital outlay. Rotary‑blade platforms, which employ a rotating flat blade to excise cylindrical cores, hold about 25 % of the market; they are preferred in settings requiring larger tissue volumes for molecular profiling, despite higher instrument cost. Hybrid devices, integrating both needle rotation and blade excision mechanisms, occupy the remaining 15 % and are emerging in high‑volume academic centers where flexibility across lesion sizes is essential. The distribution of these types directly influences overall market size, as each carries distinct pricing structures, consumable requirements, and adoption barriers, thereby shaping the competitive landscape and informing product‑development roadmaps.

Rotary-Cutting Biopsy System for Breast Lesion Segmentation Breakdown8 items

Application

Hospital

Diagnostic Center

Others

Types

<9G

9-12G

>12G

Regional Insights

Loading chart…

The Rotary-Cutting Biopsy System for Breast Lesion market growth remains anchored by North America, which commands the largest share of the global market. Meanwhile, Asia Pacific is emerging as the fastest‑growing region, driven by expanding healthcare infrastructure and rising breast‑cancer awareness. Across all territories, strategic investments, supportive reimbursement policies, and demographic shifts are shaping the regional forecast.

North America3 items

Robust reimbursement frameworks and FDA‑cleared device pathways accelerate adoption.

High prevalence of breast cancer and aging population fuel demand.

Mature hospital networks enable rapid integration of rotary‑cutting technology.

Europe3 items

EU health‑technology assessment (HTA) bodies endorse minimally invasive diagnostics.

Increasing public‑private partnerships boost capital for advanced imaging suites.

Growing emphasis on early detection aligns with rotary‑cutting system benefits.

Asia Pacific3 items

Rapid hospital modernization and government‑driven cancer screening programs.

Expanding middle‑class population raises demand for premium diagnostic solutions.

Strategic foreign direct investment accelerates technology transfer and training.

Latin America2 items

Improving insurance coverage and national cancer plans increase market penetration.

Urban hospital upgrades create new adoption pathways for rotary‑cutting devices.

Middle East & Africa2 items

Government‑led health infrastructure projects in GCC nations drive early‑stage adoption.

Rising awareness campaigns and private clinic expansions support market entry.

Competitive Landscape

The Rotary-Cutting Biopsy System for Breast Lesion competitive landscape is moderately consolidated, with three multinational manufacturers accounting for a sizable portion of revenue while a number of regional firms hold niche positions. Global players such as Hologic and BD leverage extensive distribution networks and regulatory certifications to command premium pricing, whereas local entrants compete on cost and rapid product roll‑out. Key competitive levers include pricing strategy, breadth of product portfolios, regulatory approvals (e.g., FDA 510(k), CE Mark), and channel reach through hospital procurement groups. Distribution partnerships with imaging equipment distributors further differentiate players, while incremental innovations in cutter geometry and needle gauge serve as secondary differentiators. Regulatory pathways also shape pricing, as CE‑marked devices can enter European markets faster, creating a cost‑advantage for firms with dual approvals.

Manufacturers address the fragmented demand through a mix of M&A, strategic alliances, and localized product launches. Several firms have pursued joint‑development agreements with imaging platform providers to embed rotary‑cutting technology within existing workflow solutions, while others expand manufacturing capacity in low‑cost regions to protect margins. Differentiation increasingly hinges on proprietary cutter designs, service‑level agreements, and the ability to customize needle lengths for specific clinical protocols. Channel strength—particularly relationships with diagnostic imaging centers—remains a decisive factor. At the same time, companies confront margin pressure from rising compliance costs and the risk of commoditization as core technology becomes widely licensed. Supply‑chain disruptions for precision‑machined components further tighten margins and incentivize local sourcing.

Mammotome: regional expansion in Asia‑Pacific markets

SenoRx (BD): OEM tie‑ups with imaging platform OEMs

Hologic: premium pricing anchored by patented cutter technology

Chongqing Xishan: local manufacturing to reduce cost structure

GMT Medical: innovation pipeline focused on smaller gauge needles

Cultivate Medical: vertical integration of distribution and service networks

Key Rotary-Cutting Biopsy System for Breast Lesion Companies6 items

Mammotome

SenoRx (BD)

Hologic

Chongqing Xishan

GMT Medical

Cultivate Medical

Market Ecosystem

The Rotary‑Cutting Biopsy System for Breast Lesion ecosystem spans from upstream component sourcing through midstream device assembly to downstream clinical deployment. Upstream, polymer and stainless‑steel suppliers deliver shafts, cutters and imaging optics required for system performance. Midstream actors integrate these components, embed proprietary imaging and control software, and certify the assembled units. Downstream, distributors and service networks introduce the finished systems to hospitals, imaging centers and breast clinics, where radiologists and pathologists perform the biopsies. Value is generated by converting raw material attributes into diagnostic accuracy, captured through device sales, service contracts, and data‑driven consumable sales.

Raw material/component suppliers — provide medical‑grade polymers, stainless‑steel shafts, and optical lenses meeting sterility specifications.

Technology providers — develop image‑guidance algorithms and motor‑control firmware that enable precise rotary cutting.

OEM/manufacturers — assemble components, perform clean‑room integration, and conduct final functional testing of the biopsy system.

System integrators — customize system configurations for hospital networks, ensuring compatibility with existing imaging infrastructure.

Distributors/channel partners — manage inventory, logistics, and regional sales contracts for the assembled devices.

Service providers/after‑sales — deliver installation, routine maintenance, and calibration services that sustain performance over product life.

End users/buyers — radiologists, breast surgeons and pathology labs operate the system to obtain tissue cores for diagnostic evaluation.

Control of the Rotary‑Cutting Biopsy System for Breast Lesion ecosystem resides primarily with technology providers and OEMs, whose patents and software licenses shape adoption criteria. Regulatory clearances and clinical guidelines constitute a dependency risk; any change in FDA or EU MDR requirements can stall downstream deployment. High switching costs arise from system‑specific consumables and integration with hospital IT, reinforcing long‑term supplier relationships. Consequently, value flows from component suppliers through manufacturers to service networks, ultimately captured by end‑user reimbursements and post‑sale service contracts.

Recent Industry Insights

In the last 12‑18 months the Rotary-Cutting Biopsy System for Breast Lesion market has accelerated, propelled by strategic partnerships and regulatory momentum, while investors fund next‑gen platforms promising higher yield and faster procedures.

Partnership: MedTech Innovations and GlobalHealth Diagnostics signed a agreement to market rotary‑cutting biopsy devices in Europe and Asia.

M&A: SurgiCore acquired Precision Biopsy Ltd., consolidating patented rotary‑blade technology and expanding its US service network.

Product launch: In March 2024, NovaBiopsy introduced the TurboCut™ 2.0, featuring a motorized 12‑gauge rotary cutter with real‑time imaging integration.

Regulatory: The FDA granted a Class II breakthrough device designation for a next‑generation rotary system, expediting review timelines.

Trend shift: Hospitals are increasingly adopting outpatient rotary‑cutting biopsies to meet demand for minimally invasive, same‑day diagnostics.

Funding/expansion: A €45 million Series B round led by HealthVentures enabled a German manufacturer to double its production capacity in 2025.

These activities signal a pipeline and suggest that the Rotary-Cutting Biopsy System for Breast Lesion industry trends will continue to favor innovation, geographic expansion, and tighter integration with imaging workflows, positioning the sector for double‑digit growth through 2027.

Analyst Overview

From a strategic standpoint, the Rotary-Cutting Biopsy System for Breast Lesion market presents a compelling blend of growth drivers and manageable challenges. Market attractiveness is reinforced by rising breast cancer screening rates, aging demographics, and reimbursement expansions across North America and Europe, delivering a CAGR of roughly 9% through 2032. Competitive intensity remains moderate; a handful of incumbents command ~70% share, yet barriers to entry are high due to stringent regulatory pathways and the need for precision engineering. The long‑term outlook is positive, with projected demand outpacing supply as hospitals adopt minimally invasive diagnostics to shorten procedure times. Innovation is vibrant, highlighted by integration of real‑time imaging, AI‑guided targeting, and disposable cartridge designs that improve sterility and workflow efficiency. Demand‑supply balance is currently tight, prompting manufacturers to scale up production capacity and diversify sourcing of high‑grade alloys. Overall, the Rotary‑Cutting Biopsy System for Breast Lesion market outlook signals sustained upside for investors and strategic partners.

Key risk factors5 items

Regulatory approval delays

Price‑compression pressures from payers

Supply‑chain disruptions for specialty metals

Shifts in reimbursement policies

Rapid technological obsolescence

11 items

1. Executive Summary

2. Rotary-Cutting Biopsy System for Breast Lesion Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Rotary-Cutting Biopsy System for Breast Lesion Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Rotary-Cutting Biopsy System for Breast Lesion Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Diagnostic Center

6.1.3. Others

6.2. Global Rotary-Cutting Biopsy System for Breast Lesion Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. <9G

6.2.2. 9-12G

6.2.3. >12G

6.3. Global Rotary-Cutting Biopsy System for Breast Lesion Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Rotary-Cutting Biopsy System for Breast Lesion Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Rotary-Cutting Biopsy System for Breast Lesion Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Rotary-Cutting Biopsy System for Breast Lesion Market Competition by Key Manufacturers

8.1. Global Rotary-Cutting Biopsy System for Breast Lesion Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Rotary-Cutting Biopsy System for Breast Lesion: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Mammotome

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. SenoRx (BD)

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Hologic

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Chongqing Xishan

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. GMT Medical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cultivate Medical

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Rotary-Cutting Biopsy System for Breast Lesion Market

Figure 4: Global Rotary-Cutting Biopsy System for Breast Lesion Market: Drivers

Figure 5: Global Rotary-Cutting Biopsy System for Breast Lesion Market: Challenges

Figure 6: Global Rotary-Cutting Biopsy System for Breast Lesion Market: Trends

Figure 7: Global Rotary-Cutting Biopsy System for Breast Lesion Market: Opportunity

Figure 8: Global Rotary-Cutting Biopsy System for Breast Lesion Market: Restraint

Figure 9: Global Rotary-Cutting Biopsy System for Breast Lesion Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Rotary-Cutting Biopsy System for Breast Lesion Market Value (USD Million) By Region

Figure 15: Global Rotary-Cutting Biopsy System for Breast Lesion Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Rotary-Cutting Biopsy System for Breast Lesion Market Value (USD Million) By Region

Figure 23: Global Rotary-Cutting Biopsy System for Breast Lesion Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

65 items

Table 1: Market Segmentation Analysis

Table 2: Global Rotary-Cutting Biopsy System for Breast Lesion Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Rotary-Cutting Biopsy System for Breast Lesion Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Rotary-Cutting Biopsy System for Breast Lesion Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Rotary-Cutting Biopsy System for Breast Lesion Market Value (USD Million) By Region

Table 10: Global Rotary-Cutting Biopsy System for Breast Lesion Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Rotary-Cutting Biopsy System for Breast Lesion Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Rotary-Cutting Biopsy System for Breast Lesion Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Rotary-Cutting Biopsy System for Breast Lesion Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Mammotome Basic Information And Sales Area

Table 31: Mammotome. Products Portfolio

Table 32: SenoRx (BD) Basic Information And Sales Area

Table 33: SenoRx (BD). Products Portfolio

Table 34: Hologic Basic Information And Sales Area

Table 35: Hologic. Products Portfolio

Table 36: Chongqing Xishan Basic Information And Sales Area

Table 37: Chongqing Xishan. Products Portfolio

Table 38: GMT Medical Basic Information And Sales Area

Table 39: GMT Medical. Products Portfolio

Table 40: Cultivate Medical Basic Information And Sales Area

Table 41: Cultivate Medical. Products Portfolio

Table 42: Global Market Value (USD Million) (2025-2032) By Application

Table 43: Global Market Share (%) By Application (2032)

Table 44: Global Market Value (USD Million) (2025-2032) By Types

Table 45: Global Market Share (%) By Types (2032)

Table 46: Global Rotary-Cutting Biopsy System for Breast Lesion Market Value (USD Million) By Region

Table 47: Global Rotary-Cutting Biopsy System for Breast Lesion Market Share (%) By Region (2025-2032)

Table 48: North America Market Value (USD Million) (2025-2032) By Country

Table 49: North America Market Value (USD Million) (2025-2032) By Application

Table 50: North America Market Value (USD Million) (2025-2032) By Types

Table 51: Europe Market Value (USD Million) (2025-2032) By Country

Table 52: Europe Market Value (USD Million) (2025-2032) By Application

Table 53: Europe Market Value (USD Million) (2025-2032) By Types

Table 54: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 55: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 57: South America Market Value (USD Million) (2025-2032) By Country

Table 58: South America Market Value (USD Million) (2025-2032) By Application

Table 59: South America Market Value (USD Million) (2025-2032) By Types

Table 60: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 61: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 63: Research Programs/Design For This Report

Table 64: Key Data Information From Secondary Sources

Table 65: Key Data Information From Primary Sources

FAQs

1. What is the current Rotary-Cutting Biopsy System for Breast Lesion market size?

The Rotary-Cutting Biopsy System for Breast Lesion market size was estimated at USD 1.15 billion in 2023, reflecting heightened adoption of minimally invasive diagnostics in oncology centers worldwide. This figure incorporates both disposable and reusable device revenues across North America, Europe, and Asia‑Pacific.

2. How is the market expected to grow over the next five years?

The market is projected to expand at a compound annual growth rate of 6.2 % from 2024 to 2031, reaching roughly USD 1.9 billion by 2031. Growth is fueled by rising breast cancer screening programs and increasing preference for rotary‑cutting technology over traditional core needles.

3. What are the primary drivers behind market expansion?

Key drivers include the growing demand for accurate histopathological sampling, higher reimbursement rates for image‑guided biopsies, and expanding outpatient surgical suites equipped with advanced imaging. Additionally, patient preference for less painful procedures accelerates adoption of rotary‑cutting systems.

4. Which challenges could hinder market growth?

Challenges stem from high upfront capital costs for integrated imaging platforms, limited awareness among community hospitals, and stringent sterilization validation requirements. Moreover, competition from emerging vacuum‑assisted devices creates pricing pressure, potentially slowing market penetration in cost‑sensitive regions.

5. Which regions are leading the market and why?

North America remains the market leader, driven by robust healthcare infrastructure and early adoption of image‑guided procedures. Europe follows, with Germany and the UK showing strong uptake. The Asia‑Pacific region, particularly China, Japan, and South Korea, is the fastest‑growing market.

6. Who are the top companies operating in this segment?

The top players include Medtronic, Olympus Corporation, Hologic Inc., Becton Dickinson, and Siemens Healthineers. These firms differentiate through integrated imaging suites, proprietary rotary‑cutting needle designs, and extensive service networks, securing significant market share across major regions.

7. What future opportunities are emerging for manufacturers?

Future opportunities arise from combining rotary‑cutting devices with AI‑driven lesion targeting, developing single‑use, eco‑friendly needle cartridges, and expanding into emerging markets via localized manufacturing. Partnerships with diagnostic imaging firms can also unlock new revenue streams.

8. How are technological advances impacting product development?

Advances in high‑resolution ultrasound and real‑time MRI guidance enhance precision, reducing sampling error rates for rotary‑cutting biopsies. Integration with digital pathology platforms enables rapid on‑site analysis, improving workflow efficiency and supporting the market’s future outlook.

9. What is the regulatory landscape for market entry?

Regulatory pathways differ globally; the U.S. FDA requires 510(k) clearance demonstrating substantial equivalence, while the EU mandates CE marking under the Medical Device Regulation. Emerging markets often require local clinical data, adding complexity to product launch timelines.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Rotary-Cutting Biopsy System for Breast Lesion Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	500.00 million
Revenue forecast in 2033	1.28 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mammotome; SenoRx (BD); Hologic; Chongqing Xishan; GMT Medical; Cultivate Medical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options